Pancreatic neuroendocrine tumors (pNETs), or islet cell tumors, are a type of cancer that starts in the pancreas. Pancreatic NETs are a less common type of pancreatic cancer. They are less than 2% of ...

The prescribed dosage for Sandostatin (octreotide acetate) may depend on a person’s individual treatment plan. Factors such as your medical history may affect your dosage of Sandostatin. Sandostatin ...

Peptide receptor radionuclide therapy (PRRT) is used for the management of neuroendocrine tumors (NETs) not responsive to somatostatin analogs. In this case series, we report two patients with ...

WDHA syndrome was named for some of the characteristic symptoms of VIPoma: watery diarrhea, hypokalemia, and achlorhydria. Treatment Options for VIP-Associated Diarrhea and Flushing Patients with ...

Somatostatinomas are a rare type of malignant tumor that grows in or around the pancreas. Doctors may also call them neuroendocrine tumors (NET) or islet cell tumors. These tumors secrete large ...

where in the body the tumour is whether it overproduces hormones or not (functioning or non-functioning). Non-functioning NETs do not overproduce hormones. They may cause symptoms such as pain if they ...

A pancreatic neuroendocrine tumor (PNET) develops in the pancreas from a type of cell known as a neuroendocrine, or an endocrine, cell. These cells manufacture and release hormones such as insulin and ...

A pancreatic neuroendocrine tumor (NET) is a type of cancer that forms tumors in the pancreas. The pancreas is a gland that rests behind the stomach and in front of the spine. It has two main parts.

Vasoactive intestinal peptide (VIP) secreting tumor (VIPoma) constitutes a rare functional neuroendocrine tumor that most often originates from pancreatic islet cells and presents as a sporadic, ...

Gene expression profiling (GEP) to predict the primary site of metastatic neuroendocrine tumors (NETs) presenting with an unknown primary. This is an ASCO Meeting Abstract from the 2013 ASCO Annual ...

Pancreatic neuroendocrine tumors (pancreatic NETs or PNETs) account for around 8%* of all pancreatic tumors. They may be benign or malignant and they tend to grow slower than exocrine tumors. They ...